Balanced news tone
News Sentiment
XNCR sentiment intelligence
Xencor Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
80/100 classification confidence.
directly relevant articles
high-authority source matches
+5.7% over one week, +28.5% over four weeks, trend inactive, and near fair-value range.
Pharmaceutical Method-of-Use Claims After Teva v. Eli Lilly and In re Xencor: Written Description, Enablement, and the Known-Compound Genus
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Xencor (XNCR) director’s 10b5-1 sale covers 6,843 common shares
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 07:00
- Source
- Stock Titan
Xencor, Inc. Files 8-K: Company Details, Stock Info, and Executive Plan Updates for 2026
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 07:00
- Source
- Minichart
[144] Xencor Inc SEC Filing
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 07:00
- Source
- Stock Titan
Xencor (NASDAQ: XNCR) investors back 4M-share equity plan boost and all proposals
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 07:00
- Source
- Stock Titan
Xencor (XNCR) director sells 5,474 shares under Rule 10b5-1 plan
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 07:00
- Source
- Stock Titan
Director at Xencor (XNCR) sells 7,527 shares under 10b5-1 plan
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 07:00
- Source
- Stock Titan
Xencor (XNCR) Stock Draws Fresh Price Target Split As Pipeline Progress Meets Caution
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 14 Jun 2026 05:11
- Source
- Simply Wall St.
Xencor Inc stock (US98401F1057): shares react to Monjuvi first-line lymphoma update and recent Q1 20
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jun 2026 07:00
- Source
- Ad Hoc News
XNCR - Xencor Inc Stock Price and Quote
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 May 2026 07:57
- Source
- Finviz
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Bi/Multispecific Drugs in Oncology Analytical Tool Featuring Top Developers - Amgen, Hoffmann-La Roche, J&J, Xencor, Biocytogen - Unlocking New Precision, Immune Activation, and Therapeutic Potential
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 May 2026 09:22
- Source
- GlobeNewswire
These Analysts Just Made A Huge Downgrade To Their Xencor, Inc. (NASDAQ:XNCR) EPS Forecasts
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
These Analysts Think Xencor, Inc.'s (NASDAQ:XNCR) Sales Are Under Threat
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 May 2026 11:11
- Source
- Simply Wall St.
Xencor: Q1 Earnings Snapshot
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 06 May 2026 20:08
- Source
- Associated Press
Xencor Highlights XmAb942 Phase 1 Data, Previews TL1A/IL-23 Bispecific XmAb412 at DDW 2026
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 May 2026 10:12
- Source
- MarketBeat
Xencor Reports First Quarter 2026 Financial Results
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 06 May 2026 07:00
- Source
- Business Wire
Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 06 May 2026 07:00
- Source
- Market source
Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 May 2026 07:00
- Source
- Business Wire
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Xencor stock downgraded to neutral at JPMorgan on execution concerns
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Mar 2026 07:00
- Source
- Investing.com
What Catalysts Are Rewriting The Xencor (XNCR) Story In A Recovering Biopharma Sector
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Feb 2026 08:00
- Source
- Market source
What Xencor (XNCR)'s 2026 XmAb Pivotal Plans and Cash Runway Through 2028 Mean For Shareholders
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 13 Jan 2026 08:00
- Source
- simplywall.st
Is Xencor (XNCR) Now Fairly Priced After Prolonged Share Price Declines
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 08 Jan 2026 08:00
- Source
- simplywall.st